Naproxen is widely recommended as first-line medication for endo-associated pain by ACOG, NICE, ESHRE and others, with strong evidence for menstrual pain generally but surprisingly thin endo-specific evidence. The 2015 Cochrane review of 80 RCTs confirmed NSAIDs significantly outperform placebo for primary dysmenorrhoea. For endo specifically, the 2017 Cochrane review found only one small RCT (Kauppila 1985) and concluded evidence was insufficient — not because NSAIDs don't work, but because they've never been properly tested in endo. Naproxen has mid-range GI risk among NSAIDs (higher than ibuprofen, lower than ketorolac). Take with food, ideally before period onset, and consider adding a PPI for regular use.
Research status
Some Evidence
Endo-specific
Partial
Community signal
Mixed
How does Naproxen work?
Naproxen is a non-selective inhibitor of cyclooxygenase (COX) enzymes COX-1 and COX-2. In dysmenorrhoea and endometriosis, this works by: (1) Blocking prostaglandin synthesis — prostaglandins (particularly PGF2α and PGE2) drive uterine hypercontractility, vasoconstriction, ischaemia, and the inflammatory cascade underlying menstrual pain. Women with dysmenorrhoea have measurably elevated endometrial prostaglandin levels; (2) Reducing inflammatory mediators at endometriotic lesions — endo lesions produce COX-2 in large quantities, contributing to local inflammation; (3) Peripheral analgesic effects reducing sensitisation of pain receptors. Naproxen has a relatively long half-life (~14 hours) compared to ibuprofen (~2 hours), meaning less frequent dosing — typically BD rather than QDS. Its effect on COX-1 explains both its anti-platelet effects and its GI side effect profile.
What does the research show about Naproxen for endometriosis?
Below are studies linked to this intervention in our database, with design, quality, and outcomes summarised for quick scanning. Endo-specific evidence in this entry: Partial.
16 studies
Standardizing medical pain management for the endometriosis patient: A Dutch modified eDelphi procedure
van Haaps et al. · 2026
SurveyEndometriosis-specificQuality: High
2026 Dutch consensus guideline. Endorses NSAIDs as step 1 of WHO pain ladder for endo. Specifically recommends co-prescribing a PPI with NSAIDs for stomach protection.
Standardizing medical pain management for the endometriosis patient: A Dutch modified eDelphi procedure
van Haaps et al. · 2026
SurveyEndometriosis-specificQuality: High
2026 Dutch consensus guideline. Endorses NSAIDs as step 1 of WHO pain ladder for endo. Specifically recommends co-prescribing a PPI with NSAIDs for stomach protection.
Comparative Analysis of Medical Interventions to Alleviate Endometriosis-Related Pain: A Systematic Review and Network Meta-Analysis
Csirzó Á et al. · 2024
Meta-analysisEndometriosis-specificQuality: Medium
Network meta-analysis of 45 RCTs comparing 16 medical interventions for endometriosis-related pain. For dysmenorrhoea specifically, GnRH agonists combined with combined hormonal contraceptives ranked highest at 6 months (p-score 0.649). NSAIDs included as comparator with established efficacy. Positions NSAIDs within contemporary medical treatment landscape for endo pain.
Comparative Analysis of Medical Interventions to Alleviate Endometriosis-Related Pain: A Systematic Review and Network Meta-Analysis
Csirzó Á et al. · 2024
Meta-analysisEndometriosis-specificQuality: Medium
Network meta-analysis of 45 RCTs comparing 16 medical interventions for endometriosis-related pain. For dysmenorrhoea specifically, GnRH agonists combined with combined hormonal contraceptives ranked highest at 6 months (p-score 0.649). NSAIDs included as comparator with established efficacy. Positions NSAIDs within contemporary medical treatment landscape for endo pain.
Dysmenorrhea: a Narrative Review of Therapeutic Options
Kirsch E et al. · 2024
Systematic reviewNot endo-specificQuality: Medium
Narrative review of dysmenorrhoea management. Places NSAIDs firmly as first-line pharmacologic treatment via COX inhibition blocking prostaglandin formation. Identifies heat therapy and physical exercise as non-pharmacological treatments with strong evidence alongside NSAIDs. Emphasises multi-modal approach as likely providing the most benefit for women with severe menstrual pain.
Dysmenorrhea: a Narrative Review of Therapeutic Options
Kirsch E et al. · 2024
Systematic reviewNot endo-specificQuality: Medium
Narrative review of dysmenorrhoea management. Places NSAIDs firmly as first-line pharmacologic treatment via COX inhibition blocking prostaglandin formation. Identifies heat therapy and physical exercise as non-pharmacological treatments with strong evidence alongside NSAIDs. Emphasises multi-modal approach as likely providing the most benefit for women with severe menstrual pain.
Disease Burden of Dysmenorrhea: Impact on Life Course Potential
MacGregor B et al. · 2023
Systematic reviewNot endo-specificQuality: Medium
Recent clinical review of dysmenorrhoea from University of British Columbia Endometriosis and Pelvic Pain Centre. Confirms NSAIDs and combined hormonal contraceptives as most common pharmacologic management. Notes that untreated dysmenorrhoea can lead to hyperalgesic priming predisposing to chronic pelvic pain — supporting early and adequate analgesic treatment.
Disease Burden of Dysmenorrhea: Impact on Life Course Potential
MacGregor B et al. · 2023
Systematic reviewNot endo-specificQuality: Medium
Recent clinical review of dysmenorrhoea from University of British Columbia Endometriosis and Pelvic Pain Centre. Confirms NSAIDs and combined hormonal contraceptives as most common pharmacologic management. Notes that untreated dysmenorrhoea can lead to hyperalgesic priming predisposing to chronic pelvic pain — supporting early and adequate analgesic treatment.
Systematic reviewEndometriosis-specificQuality: High
American Family Physician 2022 review of endometriosis evaluation and management. Confirms NSAIDs with combined hormonal contraceptives as first-line medical therapy for endometriosis pain. Notes tolerable adverse effect profile and places NSAIDs at the start of a stepped care algorithm before considering second-line options (GnRH agonists/antagonists, danazol).
Systematic reviewEndometriosis-specificQuality: High
American Family Physician 2022 review of endometriosis evaluation and management. Confirms NSAIDs with combined hormonal contraceptives as first-line medical therapy for endometriosis pain. Notes tolerable adverse effect profile and places NSAIDs at the start of a stepped care algorithm before considering second-line options (GnRH agonists/antagonists, danazol).
What do people in online endo communities say about Naproxen?
Community signals are indicative only — they reflect informal conversation in endometriosis-focused spaces. People posting may or may not have a formal diagnosis; this is not a substitute for clinical evidence or care.
Reddit
Mixed · 800 mentions
HealthUnlocked
Mixed · 600 mentions
“Naproxen genuinely takes the edge off if I take it the day before my period starts. If I wait until I'm in pain it does nothing.”
— Reddit
“It does nothing for me. I might as well be eating Tic Tacs. Switched to mefenamic acid and that actually works.”
— Reddit
“Started omeprazole alongside it after a year of stomach issues. Wish someone had told me earlier — the GI side effects with regular use are no joke.”
— Reddit
“Naproxen 500mg twice a day was my GP's first move. It takes the edge off the heavy pressure feeling but doesn't touch the deep pain.”
— HealthUnlocked
“I had really bad side effects from naproxen. I work in anaesthesia so I knew to stop. Always take with food and ask for stomach protection.”
— HealthUnlocked
“Mefenamic acid is my miracle drug. Naproxen did nothing for me. Worth trying different NSAIDs because everyone responds differently.”
— HealthUnlocked
How is Naproxen typically used?
Practical notes
Typical adult dose for menstrual/endo pain: 500mg initial dose, then 250-500mg every 6-12 hours, max 1,250mg/day. Over-the-counter form (naproxen sodium) typically 220mg per tablet. Start EARLY — ideally 1-2 days before expected period onset, because prostaglandin levels rise before symptom onset and NSAIDs work better preventively than reactively. Take WITH FOOD to reduce gastric irritation. The 2026 Dutch consensus recommends co-prescribing a proton pump inhibitor (omeprazole, pantoprazole) with NSAIDs for gastric protection, especially for regular/chronic use. Combining with continuous topical heat has additive effect (heat RCT: faster pain onset than NSAID alone). Can be combined with paracetamol for additional relief without overlap. Avoid in: peptic ulcer disease (current or past), severe heart failure, severe renal impairment, late pregnancy, aspirin-sensitive asthma. Caution with: hypertension, moderate renal impairment, concurrent anticoagulants/SSRIs (bleeding risk), aspirin (reduces aspirin cardioprotection). Cost: very cheap — £2-5/month OTC; free on NHS prescription.
What should you know before trying Naproxen?
GI risk is the main concern with naproxen: the 2012 SOS project meta-analysis (Castellsague) quantified naproxen's upper GI complication risk at RR 4.10 (95% CI 3.22-5.23), meaningfully higher than ibuprofen (RR 1.84) but lower than piroxicam or ketorolac. For endo patients who need NSAIDs regularly for years, this cumulative GI risk matters — hence the Dutch 2026 guideline recommendation to co-prescribe a PPI. Cardiovascular profile is relatively favourable among NSAIDs (the PRECISION trial found naproxen non-inferior to celecoxib for CV events, and it's often considered the "safest" NSAID for CV risk), but any long-term NSAID use carries some cardiovascular and renal risk. The Oladosu 2020 finding that serum naproxen concentrations vary dramatically between women with similar dosing suggests "NSAID non-response" may sometimes reflect pharmacokinetic issues rather than true treatment failure — switching to a different NSAID or trying a higher dose (within licensed limits) may help before assuming the whole class is ineffective. No tolerance develops, but chronic daily use is not ideal — NSAIDs are best used cyclically around menstruation rather than continuously.
Related interventions
Other interventions in our database that target similar symptoms or fall under the same category as Naproxen.